Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

AMAG Pharma Submits SNDA To FDA For Ferahame Inj.

RELATED NEWS
Trade AMAG now with 

AMAG Pharmaceuticals, Inc. (AMAG: Quote) Monday said it has submitted a supplemental new drug application, or sNDA, to the Food and Drug Administration, for Feraheme Injection.

The sNDA proposes expansion of indications for the Ferahame, or ferumoxytol, injection for a treatment of iron deficiency anemia in adult patients with IDA who have failed or could not tolerate oral iron treatment.

The sNDA submission includes data from a global phase III program that evaluated the use of ferumoxytol in a broad range of adult IDA patients, all of whom had failed or could not tolerate oral iron treatment. More than 1,400 patients were enrolled in the two phase III clinical trials.

The regulatory approval of Feraheme for a broader IDA patient population would expand the company's market opportunity in the existing U.S. IV iron market, beyond its current CKD indication.

Click here to receive FREE breaking news email alerts for AMAG Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks may move to the upside at the start of trading on Friday, extending the recovery from yesterday's early sell-off. The major index futures are currently pointing to a modestly higher open, with the Dow futures up by 17 points. Today, 54 per cent of the world's population lives in urban areas, a proportion that is expected to increase to 66 per cent by the middle of this century, the United Nations reports. That means an additional 2.5 billion people are to live in urban areas by 2050. The Population Division of the UN Department of Economic and Social Affairs said in its 2014 revision of the World Urbanization Prospect While Republicans have repeatedly called on President Barack Obama to address the ongoing crisis along the U.S.-Mexico border, GOP leaders from both houses of Congress have stated they will not give the president a "blank check."
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.